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ABSTRACT
Hyperactive Ras signaling has strong oncogenic effects causing several different 
forms of cancer. Hyperactivity is frequently induced by mutations within Ras 
itself, which account for up to 30% of all human cancers. In addition, hyperactive 
Ras signaling can also be triggered independent of Ras by either mutation or by 
misexpression of various upstream regulators and immediate downstream effectors. 
We have previously reported that C-kinase potentiated protein phosphatase-1 inhibitor 
of 17 kDa (CPI-17) can drive Ras activity and promote tumorigenic transformation 
by inhibition of the tumor suppressor Merlin. We now describe an additional element 
of this oncogenic mechanism in the form of the ezrin-radixin-moesin (ERM) protein 
family, which exhibits opposing roles in Ras activity control. Thus, CPI-17 drives Ras 
activity and tumorigenesis in a two-fold way; inactivation of the tumor suppressor 
merlin and activation of the growth promoting ERM family. The in vivo significance 
of this oncogenic switch is highlighted by demonstrating CPI-17’s involvement in 
human melanoma pathogenesis.
INTRODUCTION
The small GTPase Ras is a central signaling 
component that translates a multitude of extracellular 
stimuli into well-deﬁned cellular processes - including 
proliferation, migration and differentiation [1]. Aberrant 
Ras activity has strong oncogenic effects, causing several 
different forms of cancer [1-3]. Tumor cells exhibiting 
hyperactive Ras signaling are independent from 
extracellular mitogenic input, thus showing uncontrolled 
cellular growth and proliferation [1, 3]. Hyperactive Ras 
signaling is frequently induced by mutation of Ras itself 
[1-3]; Ras mutations account for up to 30% of all human 
cancers [2]. However, hyperactive Ras signaling can also 
be induced independent of Ras mutations; either through 
mutation or through misexpression of various upstream 
regulators and immediate downstream effectors [1, 2, 4, 
5].
Previously, we have reported that C-kinase 
potentiated protein phosphatase-1 inhibitor of 17 kDa 
(CPI-17) can drive Ras activity and promote tumorigenic 
transformation by inhibiting the tumor suppressor Merlin 
[6]. CPI-17 directly controls Merlin activity by regulating 
its phosphorylation status via the myosin phosphatase 
MYPT1-PP1δ. We now describe an additional element of 
this oncogenic mechanism in the form of the ezrin-radixin-
moesin (ERM) protein family. Although closely related, 
Merlin and the ERM proteins are regulated in an opposing 
manner, i.e. C-terminal phosphorylation inactivates Merlin 
but activates ERM proteins [7, 8]. Moreover, Merlin and 
ERM proteins fulﬁl opposing roles in Ras activity control; 
while Merlin restricts Ras activity [5], ERM proteins are 
essential for proper Ras activation [9-11]. Here we show 
that ERM proteins, like Merlin, are regulated by a CPI-
17 - MYPT1-PP1δ switch, which results in hyperactive 
Ras signaling and tumorigenic growth. Thus, we report 
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CPI-17 as a potent oncogene driving Ras activity and 
tumorigenesis in a two-fold way - inactivation of the 
tumor suppressor Merlin and activation of the growth 
promoting ERM family. Consequently, we ﬁnd that 
misexpression of CPI-17 in a cell line physiologically 
devoid of CPI-17 sufﬁces to drive Ras activity as well as 
cellular transformation. 
Moreover, we have previously reported 
misexpression of CPI-17 in different cancer cell lines, 
including Recurrent Primary Malignant Melanoma 
cells (RPM-MC) [6]. We now provide further evidence 
demonstrating CPI-17’s involvement in human melanoma 
pathogenesis by reporting frequent misexpression in 
primary patient-derived melanoma tissue and cell line 
samples. Conversely, depletion of CPI-17 in patient-
derived melanoma cell lines decreases proliferation, 
cellular transformation and hyperactive Ras signaling. 
Strikingly, we identiﬁed CPI-17 misexpression particularly 
in those samples devoid of oncogenic BRAF or NRAS 
mutations. Thus, we propose CPI-17 as a potent oncogene 
providing an alternative mechanism to drive oncogenic 
Ras signaling and tumorigenesis.
RESULTS
We previously reported that MYPT1 binds directly 
to Merlin to mediate its dephosphorylation [6]. Others 
have reported that MYPT1 can also bind directly to 
the closely related ERM family members ezrin and 
moesin in vitro [12]. Binding to moesin was additionally 
conﬁrmed within a cellular context using MDCK cells 
[12]. For this reason, we hypothesized that ezrin, too, 
is bound and regulated by MYPT1 in vivo. Indeed, 
interaction of ezrin with MYPT1 was readily detected 
by co-immunoprecipitation from HeLa cells transiently 
expressing a myc-tagged ezrin protein (Figure 1A). This 
result was further validated by afﬁnity precipitation, using 
recombinantly expressed His-tagged ezrin protein on HeLa 
lysates (Figure 1B). In order to test whether MYPT1 also 
mediates ezrin’s dephosphorylation, we downregulated 
MYPT1 expression in HeLa cells using two independent 
siRNAs. Loss of MYPT1 expression consistently yielded 
a strong increase in ezrin phosphorylation, correlating 
noticeably with the efﬁciency of MYTP1 depletion (Figure 
1C).MYPT1-dependent ezrin dephosphorylation was also 
validated by downregulation of MYPT1 expression in 
NIH3T3 mouse ﬁbroblasts (Figure 1D), using a lentiviral 
shRNA approach. Thus, in addition to Merlin, MYPT1-
PP1δ also appears to mediate dephosphorylation of the 
closely related ezrin protein and, by extension, likely the 
whole ERM protein family. 
Previously, we have reported on the tumorigenic 
potential of the MYPT1-PP1δ inhibitor CPI-17, due to 
increased phosphorylation and, thus, inactivation of the 
tumor suppressor Merlin [6]. We validated this ﬁnding by 
generating NIH3T3 ﬁbroblasts stably expressing CPI-17 
(Figure 1E-1G). As per previous results, overexpression 
of CPI-17 led to a strong increase of inhibitory Merlin 
phosphorylation (Figure 1E) and resulted in robust 
activation of the small GTPase Ras (Figure 1F). We also 
observed a marked increase in activating phosphorylation 
of ERM proteins (Figure 1G) - counter players of Merlin 
in Ras activity control [11]. Therefore, the CPI-17 - 
MYPT1-PP1δ axis may employ dual mechanisms to drive 
Ras pathway activity; inactivation of the tumor suppressor 
Merlin to release inhibition of Ras activity, and activation 
of the growth promoting ERM protein family to increase 
Ras activation. 
To test this possibility, we measured [α32P]-GTP 
loading of Ras in vivo, using streptolysin O (SLO)-
permeated cells (Figure 2A). Radioactive labeling 
of the α-phosphate allows measurement of Ras-GTP 
loading (facilitated by ERM proteins [10]), independent 
of simultaneously occurring GTP to GDP hydrolysis 
(facilitated by Merlin [5]). This enables direct measuring 
of Ras activity induction (see Material and Methods 
for details). NIH3T3 cells expressing CPI-17 showed 
signiﬁcantly faster 32P-labeling of Ras; detectable after 
30 seconds and resulting in strongly increased 32P-labeled 
Ras at all time points measured (Figure 2A). Hence, CPI-
17 not only reduces Ras inhibition due to inactivation 
of Merlin, but also drives induction of Ras activation - 
presumably due to activation of ERM proteins, which 
we previously reported to actively facilitate GTP-loading 
and, thus, activation of Ras [10]. In support of this, 
depletion of ERM proteins in CPI-17 expressing NIH3T3 
cells strongly reduced active GTP-Ras levels (Figure 
2B). Likewise, expression of a dominant negative ezrin 
mutant (ezrinR579A [13]) strongly reduced GTP-Ras 
levels (Figure 2C); further conﬁrming the requirement 
of functional, active ERM proteins for CPI-17 driven 
Ras activation. Subsequently, we tested whether CPI-17 
employs ERM proteins not only to induce Ras activity, 
but also to drive cellular transformation. To this end, we 
deprived CPI-17 expressing NIH3T3 cells of ERM protein 
functions by either siRNA-mediated ERM depletion 
(Figure 2D), or overexpression of the dominant negative 
mutant ezrinR579A (Figure 2E). Downregulation of 
ERM activity by either method provoked a signiﬁcant 
decrease in the number of colonies formed in soft agar - 
conﬁrming ERM proteins as vital contributors of CPI-17’s 
tumorigenic potential. 
Physiologically, expression of CPI-17 is restricted to 
few select cell types, primarily smooth muscle cells [14, 
15], but absent from most other cell types. In contrast, 
we previously found CPI-17 misexpressed in several 
different cancer cell lines [6], including Recurrent Primary 
Malignant Melanoma Cells (RPM-MC). Downregulation 
of CPI-17 in RPM-MC cells strongly reduced hyperactive 
Ras levels and soft agar colony formation [6], suggesting 
CPI-17’s involvement in melanoma tumorigenesis. As 
previously observed in transformed NIH3T3 ﬁbroblasts 
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Figure 1: MYPT1 regulates ERM phosphorylation. (A-B) MYPT1 readily co-precipitates with ezrin from HeLa cells. A: Ezrin 
was immunoprecipitated from HeLa cells expressing a myc-tagged ezrin. B: MYPT1 was precipitated from HeLa cells using recombinant 
puriﬁed His-tagged ezrin coupled to Ni-Sepharose. (C) Depletion of MYPT1 in HeLa cells increases ERM phosphorylation. Two 
independent siRNAs targeting different regions of the MYPT1 mRNA were used. (D) Depletion of MYPT1 in NIH3T3 cells increases ERM 
phosphorylation. Cells stably express shRNA targeting either Luciferase (shControl) or MYPT1 mRNA (shMYPT1). (E-G) Overexpression 
of the MYPT1 inhibitor CPI-17 in NIH3T3 cells increases (E) inhibitory phosphorylation of merlin (F) induction of the small GTPase Ras 
and (G) activating phosphorylation of ERM proteins. Quantiﬁcation of band size performed by ImageJ, normalization to Actin (C-E), total 
Ras (F) or ezrin / ERM (D, G) levels.
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(Figure 2), ERM proteins appeared to be vital contributors 
to CPI-17’s tumorigenic potential in melanoma cells. 
Depletion of CPI-17 in RPM-MC cells lowered ERM 
phosphorylation (Figure 3A), while depletion of ERM 
proteins alleviated CPI-17’s effect on Ras activation 
(Figure 3B) and soft agar colony formation (Figure 3C); 
conﬁrming ERM proteins as important components of 
CPI-17’s oncogenic role in melanoma cells.
To assess the signiﬁcance and prevalence of CPI-17’s 
tumorigenic role in human melanoma pathogenesis, we 
analyzed CPI-17 expression in several melanoma-derived 
cell samples, as well as in normal human melanocytes 
previously reported in the Zürich dataset [16] (Figure 
3D). CPI-17 mRNA was overexpressed in the majority 
of samples - with two thirds (8 of 12) showing at least 
10-fold increased expression. CPI-17 was consistently 
Figure 2: CPI-17 drives Ras activation and cellular transformation via ERM proteins. (A)  GEF activity measured by 
increase of 32P-labeled Ras in streptolysin O (SLO)-permeabilized NIH3T3 cells treated with [α32P]-GTP and 10 ng/ml PDGF. (B.-E) 
Depletion of ERM protein functions by either siRNA transfection (B, D) or over expression of the dominant negative ezrinR579A (C, E) 
counters CPI-17 induced B-C: Ras activity and D-E: soft agar colony formation of NIH3T3 ﬁbroblasts.. Statistical analysis performed by 
two-tailed t-test (A: p = 0.02 / 0.15 / 0.02 / 0.0004 / 0.02 C: p < 0.05 E: p < 0.005 ) pre-requisites tested by F-test (A: p = 0.97 / 0.001 / 0.32 
/ 0.4 / <0.001 C: p > 0.89, E: p > 0.81).
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Figure 3: CPI-17 drives oncogenesis in RPM-MC cells and is frequently misexpressed in human melanoma samples. 
(A) Depletion of CPI-17 decreases ERM phosphorylation in stably transduced RPM-MC cells. (B.-C)  Depletion of ERM proteins in RPM-
MC cells by lentivirally delivered miRNA inhibits B: Ras activity and C: soft agar colony formation. (D)  Microarray analysis of CPI-17 
mRNA expression in different human melanoma samples and primary human melanocytes. Overexpression is obvious in 10 of 12 samples 
overall and 4 of 4 samples devoid of N-Ras and BRAF mutations. Microarray data was previously reported in [16] and accessed via NCBI 
GEO database [29]. Quantiﬁcation of western blots performed by ImageJ, normalization to total Ras levels. E: Misexpression of CPI-17 
protein in patient-derived melanoma cell lines, cells derived from samples used for (D). Misexpression is detectable only in BRAF V600, 
NRAS Q61 wild type cells and absent from primary human melanocytes.
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and highly overexpressed (4 of 4) in melanoma samples 
containing neither oncogenic BRAF V600E nor oncogenic 
NRas Q61K/R mutations; suggesting that Ras activity may 
primarily be driven via the CPI-17-ERM pathway in these 
cells. This assumption is supported by analysis of CPI-17 
expression and function in melanoma cell lines derived 
from the data set (Figure 3E, Figure 4). Misexpression 
of CPI-17 protein was speciﬁcally detected in melanoma 
cell lines wildtype for both the BRAF V600 and NRAS 
Q61 locus (Figure 3E; see Supplementary Figure S1 
for sequencing results of RPM-MC cells) and absent in 
primary melanocytes. Expression of the CPI-17 effectors 
ezrin, radixin and moesin appeared unchanged and no 
loss of Merlin expression was detected (Supplementary 
Figure S2). In agreement with our previous results 
obtained in RPM-MC cells, depletion of either CPI-17 
or ERM expression (Figure 4A) in M21 melanoma cells 
led to a signiﬁcant decrease in proliferation (Figure 4B), 
Figure 4: CPI-17 drives oncogenesis in patient-derived M21 melanoma cells. (A) Stable knockdown cell lines were generated 
by transducing artiﬁcial miRNA targeted against CPI-17 or ezrin, radixin and moesin (ERM) respectively. (B.-D) Depletion of either CPI-
17 or ERM proteins in M21 cells decreases B: proliferation C: Ras activity and D: soft agar colony formation. Proliferation data derived 
from six independent wells with > 1700 cells detected per well. Soft agar images are representative for three (CPI-17) or two (ERM) 
experiments with triplicates each (Supplementary Figure S3). Statistical analysis performed by two-tailed t-test (t-test: p < 5 x 10-7), pre-
requisites tested by F-test (p = 0.89 and p = 0.49, respectively).
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Ras activation (Figure 4C), and strongly inhibited cellular 
transformation (Figure 4D, Supplementary Figure S3); 
further demonstrating CPI-17’s tumorigenic potential 
involving ERM proteins in melanoma cells.
Further investigating the prevalence of CPI-17 
misexpression in human melanomas, we analyzed several 
tissue samples derived from patient material. Around 70% 
of metastatic and nodular malignant melanomas (NMM) 
- as well as 50% of superﬁcial spreading melanomas 
(SSM) - showed strong CPI-17 expression, compared to 
only 20% of benign nevi samples (Table 1). Moreover, 
delineation of the melanocytic tumor area by the HMB45 
antibody showed clear localization of CPI-17 expression 
to the tumor area, while the surrounding healthy tissue 
was negative for CPI-17 expression (representative 
images in Figure 5A-5F). Together, this data promotes 
Table 1: Melanocytic tumours positive for CPI 17 expression.
CPI-17 HMB-45
Tumor samples positive (total) positive (strong) negative positive negative
SSM 10 8 (80%) 5 (50%) 2 (20%) 8 (80%) 2 (20%)
ALM 10 8 (80%) 4 (40%) 2 (20%) 9 (90%) 1 (10%)
NMM 10 10 (100%) 7 (70%) 0 (0%) 9 (90%) 1 (10%)
LMM 9 7 (78%) 3 (33%) 2 (22%) 5 (56%) 4 (44%)
Metastatis 10 10 (100%) 7 (70%) 0 (0%) 9 (90%) 1 (10%)
Nevi (NCN) 10 6 (60%) 2 (20%) 4 (40%) 4 (40%) 6 (60%)
All tumours 59 49 (83%) 28 (47%) 10 (17%) 44 (75%) 15 (25%)
SSM: superﬁcial spreading melanoma, ALM: Acral lentiginous melanoma, NMM: nodular malignant melanoma, LMM: 
Lentigo maligna melanoma, NCN: Nevocellular Nevus
Figure 5: CPI-17 expression in human melanoma tissue samples correlates with HMB45 reactivity. (A.-F)
Immunohistochemical CPI 17 and HMB45 staining (in red) of formalin-ﬁxed parafﬁn-embedded melanoma samples. A-B: Strong staining 
of CPI-17 is observed in a melanoma metastasis and colocalizes with C: HMB45 staining speciﬁc for melanocytic tumors (C). D-E: Weak 
staining in a lentigo maligna melanoma (LMM) indicates correlation of staining intensities of CPI-17 and F: the HMB45 tumor marker 
Scale bars: A, C, D, F: 200 µm and B, E: 100 µm.
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CPI-17 as a key regulator of a novel oncogenic signaling 
cascade driving Ras activity and cellular transformation 
of melanoma cells.
DISCUSSION
This study identiﬁed ERM proteins as downstream 
targets of a regulatory CPI-17 -MYPT1-PP1δ switch 
controlling ERM phosphorylation and thus activation 
(Figure 1, Figure 3A, Figure 6). Both depletion of MPYT1 
and overexpression of its inhibitor CPI-17 were sufﬁcient 
to strongly induce ERM phosphorylation (Figure 1C, 1D, 
1G). Ezrin readily co-precipitated MYPT1 from HeLa 
lysates (Figure 1A-1B), while moesin had previously been 
reported to interact with MYPT1 in MDCK cells [12]. 
Moreover, both ezrin’s and moesin’s FERM domain were 
shown to directly bind MYPT1 in vitro [12]. Combined, 
these results indicate that MYPT1 interaction capabilities 
may be a shared feature of the entire ERM protein family, 
including radixin. 
The ERM protein family - ezrin in particular - has 
been repeatedly linked to tumorigenesis and metastatic 
progression (reviewed in [17]). High expression of ezrin 
in tumors consistently correlates with a bad prognosis, 
although the molecular mechanism often remains poorly 
understood. We have previously demonstrated that ezrin 
directly participates in the activation of the small GTPase 
Ras [10, 11]. Hyperactive Ras signaling is one of the 
most frequent drivers of tumorigenesis - up to 30% of 
all human tumors harbor Ras mutations [2]. In addition, 
mutation of Ras regulatory proteins rather than Ras itself 
offer additional mechanisms to drive oncogenic activity 
[1]. Our present study reports misexpression of CPI-17 
as an alternative mechanism to induce and/or potentiate 
oncogenic Ras pathway signaling by means of the ERM 
protein family. 
Figure 6: CPI-17 is a key regulator of a novel oncogenic signaling cascade. The CPI-17 - Myp1-PP1δ axis constitutes a 
regulatory switch between a phosphorylated, growth promoting and a dephosphorylated, growth inhibiting state of the physiological counter 
players Merlin and the ERM protein family. Subsequently, phosphorylated ERM proteins induce Ras activity while dephosphorylated 
Merlin inhibits Ras. Additional downstream targets of both Merlin and the ERM proteins suggest that CPI-17 indirectly regulates a broad 
spectrum of downstream signaling cascades.
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We previously reported CPI-17 as a driver of cellular 
transformation and tumorigenesis through inactivation of 
the tumor suppressor Merlin. In contrast to ERM proteins, 
Merlin inhibits Ras pathway signaling by promoting 
inactivation of Ras. Thus, CPI-17’s oncogenic potential 
appears to be at least two-fold - inactivation of the tumor 
suppressor Merlin and activation of the growth promoting 
ERM protein family, to drive Ras pathway activity and 
tumorigenesis (Figure 6). In addition, as recent studies 
have identiﬁed both Merlin and ERM proteins as central 
signaling hubs (reviewed in [17-19]), CPI-17 likely 
deregulates additional oncogenic pathways dependent on 
either protein (Figure 6), e.g. members of the Rho family 
GTPases such as Rac1 [5, 20, 21], RhoA [22-24], or the 
hippo pathway [25].
We note that CPI-17-induced cellular transformation 
was only partially blocked by ERM depletion in RPM-MC 
cells, suggesting the involvement of additional CPI-17-
dependent processes. For one, depletion of ERM proteins 
likely did not alleviate CPI-17-dependent inhibition of 
the tumor suppressor Merlin, thus allowing residual Ras 
activity to continue driving transformation. In support of 
this, inhibition of cellular transformation upon depletion 
of ERM proteins appeared to be stronger in the M21 
cell line (Figure 4D, Supplementary Figure S3), which 
exhibit lower Merlin protein levels than the RPM-MC 
cell line (Supplementary Figure S2). For another, while 
we have established ERM proteins (and Merlin [6]) as 
important downstream targets of the CPI-17 - MYPT1-
PP1δ axis, both CPI-17 and MYPT1-PP1δ may regulate 
additional downstream targets. Thus, other pathways 
independent of Merlin and/or ERM proteins may likewise 
be misregulated and contribute to cellular transformation 
and tumorigenesis (Figure 6) - further potentiating CPI-
17’s oncogenicity.
In the present study we have identiﬁed CPI-17 
as a potent oncogene that is frequently misexpressed 
in different types of melanocytic tumors (Figure 3D-
3E, Figure 5, Table 1). Others have reported CPI-17 to 
be frequently misexpressed in human mesothelioma 
[26] while we have reported misexpression in several 
additional cell lines derived from pancreatic, hepatic, 
ovarian or cervical carcinomas [6] - suggesting CPI-17’s 
involvement also in other tumor types. In summary, we 
propose CPI-17 to be a key regulator of an oncogenic 
signaling cascade driving tumorigenesis in multiple 
different ways. Therefore, CPI-17 should be regarded as 
a strong tumor promoter and considered as a therapeutic 
target for individualized small molecule inhibitor 
development.
MATERIALS AND METHODS
Material/reagents and kits
Recombinant human platelet-derived growth factor 
(PDGF) BB was obtained from Biomol, G418 from Life 
Technologies, Doxycycline (dox) from Sigma-Aldrich, 
Lubrol 17A17 from Uniqema, protein A agarose from 
Dianova, Ni-Sepharose 6 Fast Flow from GE Healthcare, 
Active Ras Pulldown and Detection Kit from Thermo 
Fisher Scientiﬁc. 
Antibodies
Following antibodies were used for western blotting: 
Actin (I-19), Ezrin (C-19), Radixin (C-15), Moesin (C-15), 
Merlin (B-12), MYPT1 (H-130), c-myc (9E10) from Santa 
Cruz Biotechnology; CPI-17 (E305) from Epitomics; Ezrin 
(3C12) from Neomarkers; Ezrin (3145), Radixin (C4G7), 
phospho-ERM (3149) from Cell Signaling Technology; 
Moesin (EPR2429(2)) from Abcam; phospho-NF2 S518 
from US Biologicals; VSVg from Roche. For Ras, either 
the antibody from the Active Ras Pulldown and Detection 
Kit from Thermo Fisher Scientiﬁc was used, or Ras 
(EP1125Y) from Abcam (Figure 4C). For immunoblots of 
ERM (unless otherwise stated), a mixture of Ezrin (C-19), 
Radixin (C-15) and Moesin (C-15) antibody was used; 
for single Ezrin blots, the 3C12 antibody was used. Ezrin 
(3145), Radixin (C4G7) and Moesin (EPR2429(2)) were 
used for Figures 1D, 3A, 4A and Supplementary Figure 
S2. Staining of parafﬁn sections was performed using 
anti-CPI-17 from Millipore and HMB45 from DAKO. Ras 
antibody Y13-259 (Thermo Fisher Scientiﬁc) was used for 
the GEF assay.
Plasmids
Human ezrin wildtype with C-terminal myc-tag 
was cloned in pcDNA3.1 (Invitrogen); human Ezrin 
mutant R579A with C-terminal VSVg-tag was cloned 
in pUHD10.3 rtTA responsive cloning vector (EcoR1/
Xba1) (Invitrogen). Human CPI-17 wildtype containing 
an N-terminal FLAG-tag was cloned in pcDNA3.1-V5-
His-TOPO (Invitrogen). For protein puriﬁcation, human 
ezrin wildtype with N-terminal His-tag was cloned in 
pET15TEV expression vector [10]. 
siRNAs, shRNAs and miRNAs
Down-regulation of protein expression was achieved 
as indicated either by transient transfection of short 
interfering RNA (siRNA), or stable transduction with 
lentiviral particles coding for short-hairpin RNA (shRNA) 
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under the U6 promoter, or artiﬁcial micro-RNA (miRNA) 
under a CMV promoter. siRNAs were purchased from 
Ambion (only the sense strand is reported): ezrin (mouse): 
5’-GCCGUAUGUAGACAAUAAAGG-3’; radixin 
(mouse): 5’-GCACCUCGUCUGAGAAUCAAU-3’; 
moesin (mouse): 5’- 
GCAAGCCUGACACCAUUGAGG-3’, ezrin (human): 
5’-CCCCAAAGAUUGGCUUUCC-3’, radixin (human): 
5’-GCAGUUGGAAAGGGCACAA-; moesin (human): 
5’-AAAAGCCCCGGACUUCGUC-; MYPT1 (human, 
Hs1): 5‘-GCAGGCUAUGAUGUUAAUA-3’ and MYPT1 
(human, Hs2): 5’-GAGACAAGAAAGAUUUGCU-3’; 
GL2 Luciferase siRNA was used as control: 
5‘-CGUACGCGGAAUACUUCGA- 3‘. For siRNA-
mediated triple knockdowns the amount of control siRNA 
equaled the sum of all three targeting siRNAs. Knock-
down efﬁciency was tested after 2-3 days. Following 
shRNA target sequences were used: Control (Firefly 
Luciferase): 5’- GATATGGGCTCACTGAGACT-3’; 
MYPT1 (mouse): 5’-GGAACTAACGGATCTAAAGT-3’. 
Following miRNA target sequences were used: ezrin 
(human): 5’-AACCCCAAAGATTGGCTTTCCT 
-3’, radixin (human): 
5’-AAGCAGTTGGAAAGGGCACAAT-3’; moesin 
(human): 5’-AGATCGAGGAACAGACTAAGAA-3’. 
miRNAs targeted against human CPI-17 were 
based on siRNA sequences reported previously [6]: 
5’-ACATTGATGAATTGTTGGAGTT -3’ (Hs1) and 
5’-AACCTGTCGAGGACTTCATCCA-3’ (Hs2; cloned 
in tandem). miRNAs were cloned downstream of tGFP, 
a tGFP only vector was used as control. For miRNA-
mediated double or triple knockdowns, miRNAs were 
cloned in tandem seperated by short spacer sequences on 
the same expression vector.
Cell culture
NIH3T3 (immortalized Swiss mouse embryo 
ﬁbroblasts) and HeLa (human cervix epitheloid 
carcinoma) cell lines were obtained from the European 
Collection of Animal Cell Cultures. RPM-MC (human 
recurrent primary melanoma) were a kind gift from Dr I 
Stamenkovic (MGH, Boston). M13, M18, M21 and M22 
melanoma cell lines [16] were a kind gift from Keith S. 
Hoek, University Hospital of Zürich. Human primary 
melanocytes were obtained from Lonza. NIH3T3, HeLa 
and RPM-MC cells were grown in Dulbecco’s modiﬁed 
Eagle Medium (4.5 g/L glucose, with L-glutamine, PAA 
Laboratories GmbH), supplemented with 10 % (vol/vol) 
donor calf serum (PAA Laboratories GmbH) for NIH3T3 
or fetal bovine serum (PAA Laboratories GmbH) for HeLa 
and RPM-MC. Due to change in availability, DMEM, 
RPMI and FBS from Sigmal Aldrich was used for Figures 
1D, 3A and 4A. M13, M18, M21 and M22 melanoma cell 
lines were grown in RPMI medium (with L-glutamin, 
Sigma Aldrich) supplemented with 1 mM sodium pyruvate 
(Life Technologies GmbH) and 10% (vol/vol) fetal bovine 
serum (Sigma Aldrich). Primary melanocytes were grown 
according to manufacturer’s instructions (Lonza). All cells 
were maintained in standard cell culture conditions at 37° 
C and 5 % CO2. 
Plasmid and siRNA transfection
Plasmids and siRNA were transfected with 
Lipofectamine 2000 (Life Technologies GmbH), according 
to manufacturer’s instructions. Stable clones of CPI-17 
overexpressing cells were selected by treatment with 
500 mg/ml G418 for 2 weeks and maintained thereafter 
in growth medium supplemented with G418 thereafter. 
Inducible overexpression was achieved by insertion of 
Ezrin-R579A cDNA into TetOn vector pUHD10.3 rtTA 
and expression was induced by Doxycyclin addition to the 
medium at a concentration of 1mg/ml. 
Lentiviral transduction
To generate stable knockdown cell lines, cells were 
transduced with lentiviral particles coding for tGFP and 
either shRNA under a U6 promoter or miRNA downstream 
of a CMV-driven tGFP . Virus particles were produced 
and concentrated as previously described [27]. Viral 
particles were concentrated 3-fold by polyethylene glycol 
precipitation (PEG-6000; Sigma) and used for overnight 
transduction of cells. For NIH3T3 cells, polybrene 
(Sigma) was added to a ﬁnal concentration of 8 µg/ml. 
GFP-positive cells were selected by FACS.
Expression of recombinant His-ezrin
Expression and puriﬁcation of His-ezrin has been 
previously described [10]. In brief, E. coli cells (Rosetta 
2 DE3; Novagen) were transformed with ezrin and grown 
in LB medium supplemented with antibiotics. Protein 
expression was induced for 4 h at 37 °C by addition of 
500 µM isopropyl β-d-1-thiogalactopyranoside (IPTG; 
Carl Roth GmbH) at an absorbance of 0.4-0.6 at 600 nm. 
Cells were collected by centrifugation, resuspended in a 
buffer containing 50 mM Tris (pH 8.0), 150 mM NaCl and 
protease inhibitors, before snap freezing in liquid nitrogen. 
After thawing, lysozyme (Carl Roth GmbH) was added 
and cells lysed by ultrasound. Lysates were cleared by 
centrifugation and incubated overnight with Ni-Sepharose 
6 Fast Flow (GE Healthcare). After washing with buffer 
and buffer containing 30 mM imidazole, proteins were 
eluted with buffer containing 250 mM imidazole. Eluted 
protein was dialyzed against 50 mM Tris (pH 8.0) and 150 
mM NaCl and stored at 4 °C.
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Immunoprecipitation and pull-down assays
Immunoprecipitation was performed as previously 
described [28]. In brief, HeLa cells were lysed in 50 mM 
Tris (pH 7.4), 20 mM NaCl, 0.5% Lubrol 17A17, 1 mM 
sodium vanadate, 1 mM PMSF, 10 mg/mL aprotinin and 
10 mg/mL leupeptin. Supernatants were incubated with 
2 μg of antibody rotating for 1 h at 4°C. 30 µl protein A 
agarose was added and the mixture rotated for additional 
3 h at 4°C. For pulldown of MYPT1, His-tagged 
Ezrin wildtype protein was coupled to Ni-Sepharose. 
HeLa cells were lysed in the same lysis buffer as for 
immunoprecipitation. Supernatant was incubated with 
His-Ezrin-Ni-Sepharose for 1 hour at 4°C. GTP-Ras 
pulldowns were performed using the Active Ras Pulldown 
and Detection Kit (Thermo Fisher Scientiﬁc), according 
to manufacturer’s instructions. In brief, cells were lysed 
in 25mM Tris (pH 7.2), 150 mM NaCl, 5 mM MgCl2, 1% 
NP-40, 5% (vol/vol) glycerol, 1 x complete, EDTA-free 
protease inhibitor (Roche). Supernatants were incubated 
with GST-Raf1-RBD coupled to Glutathione agarose 
rotating for 1 h at 4°C. All sepharose/agarose complexes 
were washed 4× with cold lysis buffer, dissolved in 2× 
Laemmli sample buffer and subjected to SDS PAGE. 
Proteins were detected by Western Blot analysis.
GEF activity assay
Intracellular GEF activity was measured as 
previously described [11]. In brief, NIH3T3 cells (vector 
control and CPI-17 overexpressing stable clones) were 
seeded in 6-well plates and grown to confluency. Cells 
were deprived of serum overnight, before being subjected 
to the GEF assay. Assay kinetics commenced after 
replacement of culture medium with 600 µl permeation 
buffer (50 mM HEPES pH 7.5, 107 mM K-glutamate, 23 
mM NaCl, 3 mM MgCl2, 0.3 mM CaCl2, 1 mM EGTA, 
1 mM ATP, 30 U/ml streptolysin O (Aalto Bioreagents), 
100 mCi/ml [α32P]-GTP (Hartmann Analytik) and 10 ng/
ml PDGF (except at 0 min)). At indicated time points, the 
exchange reaction was stopped by adding 1 ml lysis buffer 
(50 mM HEPES pH 7.5, 100 mM NaCl, 10 mM MgCl2, 
1% NP-40, 100 mM GDP, 100 mM GTPγS, EDTA-free 
protease inhibitor (Roche) and 5 mg/ml anti-Ras antibody 
Y13-259). Lysates were cleared by centrifugation and 
supplemented to a ﬁnal concentration of 500 mM 
NaCl, 0.6% sodium deoxycholate and 0.06% SDS. Ras 
was immunoprecipitated with protein G plus agarose 
(Oncogene). Precipitates were washed six times with 1 ml 
wash buffer (50 mM HEPES pH 7.5, 500 mM NaCl, 5 
mM MgCl2, 0.1% Triton-X-100 and 0.005% SDS) and 
subjected to Cherenkov counting.
Soft agar assay
For transformation, assays using soft agar cells were 
counted. 4 x 103 cells were suspended in 1.8 ml medium 
and 200 µl agar was added to yield a ﬁnal concentration 
of 0.33 % agar and 2 x 103 cells/ml. 500 µl of this mixture 
were seeded in triplicates into 24-Well plates, immediately 
transferred to 4°C to ensure solidiﬁcation of the agar and 
subsequently grown in a humidiﬁed cell culture incubator 
at 37°C and 5 % CO2 for two weeks. The resulting 
colonies, consisting of multiple cells, were counted. For 
M21 cells an updated protocol was used: 12-well plates 
were primed with an agarose bottom layer (800µl of 
0.5% low-melt agarose in PBS), agarose was allowed 
to set at room temperature. Cells were mixed with low-
melt agarose in complete medium at a ﬁnal concentration 
of 1.25 x 104 cells / ml, 10% FBS and 0.375% agarose 
respectively. 800 µl cell suspension (containing 1000 
cells) was layered on top of the 0.5% bottom layer. 
Agarose was allowed to set at room temperature and a 
third layer of 800µl complete medium was added. Cells 
were incubated in a humidiﬁed cell culture incubator at 
37°C and 5 % CO2 for 10 days, medium was refreshed 
once after 5 days. Cells were stained for 90 min with 
0.005% Crystal Violett in distilled water and subsequently 
rinsed twice with destilled water. Wells were imaged 
using a Canon EOS 650D mounted on a Olympus SZX10 
dissection microscope.
Proliferation assay
Proliferation of M21 cells was measured using 
the Click-iT EdU Alexa 647 HCS assay (Thermo Fisher 
Scientiﬁc) following manufacturer’s instructions. 5000 
cells per well were seeded in a black, clear bottom 96 
well plate. Six wells per cell line were seeded, cultivated 
overnight and then incubated with 10 µM EdU for 3 
hours under standard cell culture conditions. Detection 
and quantiﬁcation of EdU positive cells was performed 
using an Cellomics Arrayscan platform (Thermo Fischer 
Scientiﬁc). At least 1700 cells per well were detected by 
DAPI staining and EdU incorporation analyzed.
Statistical analysis
Statistical signiﬁcance was tested using two-tailed 
t-tests, F-tests were conducted to test the applicability 
of t-tests beforehand and accounting for differences in 
variance if neccessary. p-values of both tests are indicated 
within the respective ﬁgure legends.
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Microarray analysis
Expression of PPP1R14A mRNA coding for the 
protein CPI-17 was analyzed in different samples of 
primary human melanocytes and melanoma cells using 
the previously reported Zürich dataset [16]. The dataset 
was accessed at the NCBI GEO database [29], accession 
number GSE 4840, probe ID 227006_at. Signal intensities 
were normalized to the average of the three primary 
melanocyte samples, grouped by mutational status of 
BRAF and NRas (reported in Supplementary Data of [16]) 
and plotted in a bar chart (Figure 4A).
Amplification and sequencing of BRAF and 
NRAS sequences
RPM-MC cells grown under standard conditions 
were trypsinized, washed with PBS and pelleted by 
centrifugation. Cell lysis was performed by addition 
of 0.025 NaOH, 0.2 mM EDTA, incubation at 98 
°C for 1h and neutralization by addition of 0.04 M 
Tris-HCl. Cell lysates were used as template for Q5 
polymerase-mediated ampliﬁcation of target sequences 
following manufactor’s instructions. Primers for BRAF 
(forward 5’-GATTCTTACAGAAACAAGT-3’, reverse 
5’-AACCTAAAACCAACTCTTCCCA-3’) and NRAS 
(forward 5’-AACACATTTCAAGCCCCAAA-3’, reverse 
5’-AGCATCTCAGGGCCAAAAAT-3’) ampliﬁcation 
were based on previous reports [30]. PCR reactions were 
seperated on an agarose gel and ampliﬁed DNA fragments 
isolated and puriﬁed using the Quiaquck Gelextraction 
kit (Qiagen) following manufactor’s instructions. Isolated 
fragments were sequenced on an ABI sequencer 3730XL 
using the Big Dye Mix 3.0 according to manufacturer’s 
instruction. Ampliﬁcation primers were used for 
sequencing, as well. Sequencing information was aligned 
to the indicated reference sequences using the CLUSTAL 
OMEGA algorithm within the Benchling platform (www.
benchling.com). 
Immunohistochemical stainings
The study was conducted according to the 
Declaration of Helsinki Principles and was supported 
by informed consent of the donors. Antigen expression 
was visualized by avidin-biotin-complex-technique 
using the Supersensitive Multilink alkaline Phosphatase 
Ready-to-use Detection system (Biogenix), according to 
manufacturer’s instructions. In brief, parafﬁn sections 
were de-parafﬁnized by washing 3x in Xylol, 100% 
Ethanol, 96% Ethanol and ﬁnally 70 % Ethanol. Cold 
Methanol was used to unmask antigens. Samples were 
blocked by 2% goat serum in PBS. CPI-17 antibody was 
diluted 1:300 in blocking buffer and applied overnight 
at 4 °C. Sections were washed twice for 5 min in PBS 
+ 0.15% Tween20. Sections were incubated for 30 min 
with biotinylated anti-IgG, washed twice for 5 min in 
PBS + 0.15% Tween20, incubated for an additional 30 
min with streptavidin-AP and washed again, twice, for 
5 min in PBS/0.15% Tween20. Staining was performed 
using the New Fuchsin substrate system (Dako, Hamburg, 
Germany). Counterstaining was performed with 
hematoxylin.
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